Artelo Biosciences Adopts Solana in $9.5M ATM Raise and Secures MHRA Nod

Introduction

ARTELO BIOSCIENCES INC (Nasdaq: ARTL) is a clinical-stage pharmaceutical company focused on developing proprietary therapeutics that modulate lipid-signaling pathways. As of September 4, 2025, ARTL shares traded at $4.23 on the Nasdaq, reflecting a decrease of 51.71% with a trading volume of 149,615. The company’s pipeline includes candidates targeting conditions such as anorexia, cancer, anxiety, dermatologic disorders, pain, and inflammation.

Corporate Structure

Founded in 2017 and headquartered in La Jolla, California, Artelo Biosciences employs a small team of 2–10 individuals. The leadership comprises experienced biopharmaceutical executives who collaborate with academic researchers and technology experts. The company maintains additional offices in Dublin, Ireland, and Alderley Edge, UK, with Equiniti Trust Company, LLC serving as its transfer agent.

Biopharmaceuticals by little plant

Recent Developments and News

In the days surrounding its September 4, 2025 trading close, Artelo announced several key updates:

• On September 3, 2025, the company completed a $9.475 million at-the-market private placement, becoming the first publicly traded pharmaceutical firm to incorporate Solana (SOL) as a core reserve asset.
• The UK Medicines and Healthcare Products Regulatory Agency (MHRA) provided favorable guidance for a Phase 1 trial of ART12.11, a proprietary CBD:TMP cocrystal aimed at treating anxiety and depression.
• At the 35th Annual International Cannabinoid Research Society Symposium (#ICRS2025), Artelo presented preclinical efficacy data for ART26.12 in osteoarthritis pain.

Financial and Strategic Analysis

Artelo’s September 4, 2025 SEC filings include two prospectus supplements (Rule 424(b)(5)) and an 8-K current report. Key points include:

• The prospectus, dated September 4, 2025, reflects an amendment to the at-the-market offering cap, reducing it from $6.5 million to $3.45 million, with $451,526.95 already raised under the program.
• As of September 3, 2025, the last reported sale price for common stock was $8.76, and the aggregate market value held by non-affiliates was approximately $22 million across 774,116 shares.
• Historical ATM activity includes the sale of 50,858 shares generating gross proceeds of $451,526.95 over the prior 12 months.
• Management plans to utilize the net proceeds for ongoing research and development, clinical trials, and working capital, maintaining flexibility through at-the-market and warrant offerings.

Market Position and Industry Context

Operating within the Healthcare sector's Biotechnology industry, Artelo Biosciences occupies a niche focused on lipid-signaling modulation. Its programs—covering oncology, endocannabinoid modulation, CBD formulations, and FABP5 inhibitors—target areas with substantial unmet needs. As a clinical-stage company, Artelo competes with established biopharmaceutical firms and emerging companies in cannabinoid-related therapeutics, operating within a regulatory framework that requires rigorous safety and efficacy validation.

tl;dr

On September 3–4, 2025, Artelo Biosciences raised $9.475 million through an at-the-market placement, adopted Solana (SOL) as a treasury asset, received MHRA guidance for ART12.11's Phase 1 trial in anxiety/depression, and reported preclinical data for ART26.12 in osteoarthritis pain. The company has reduced its ATM cap to $3.45 million, holds approximately $22 million in market value among non-affiliates, and plans to allocate funds towards research and development and clinical programs. Future developments include the initiation of ART12.11's trial and milestone readouts from the pipeline.